CD8A and neoplasm: Analysis of tumor-specific T cells using the H2Kb ovalbumin (SIINFEKL) tetramer revealed that MEKi similarly reduced the number of both tumor antigen-specific CD8+ T cells (tetramer positive) and CD8+ T cells recognizing unknown antigens (tetramer negative) (Supplementary Fig. 5C).